Abstract
The safety and effectiveness of edoxaban in real-world clinical settings have not yet been elucidated thoroughly among Japanese patients with nonvalvular atrial fibrillation (NVAF). We report the one-year interim results of ETNA-AF-Japan (Edoxaban Treatment in routiNe clinical prActice in patients with nonvalvular Atrial Fibrillation: UMIN000017011), an ongoing two-year study. ETNA-AF-Japan is a prospective, real-world multicenter observational study that analyzes the long-term safety and effectiveness of edoxaban. Physicians recorded clinical characteristics, bleeding events, and clinical events of ischemic stroke and systemic embolism, among others. In total, 11 569 patients with NVAF were enrolled. The demographic and clinical characteristics of the patients in the safety analysis set (n = 11 107) were a mean age of 74.2 ± 10.0 years; female sex, 40.6%; age ≥75 years, 52.4%; body weight ≤60 kg, 54.3%; creatinine clearance ≤50 mL/min, 31.2%; mean CHADS2 score of 2.2 ± 1.3. The mean treatment period was 311.2 days (median; 366.0 days), and ~80% of patients continued edoxaban treatment. In the safety analysis, the incidence of all bleeding events was 6.32% [95% CI: 5.87, 6.79] (n = 702), and for major bleeding, it was 1.08% [0....Continue Reading
References
Jun 13, 2001·JAMA : the Journal of the American Medical Association·B F GageM J Radford
Aug 12, 2008·International Journal of Cardiology·Hiroshi InoueShiro Kamakura
Sep 1, 2009·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN RE-LY Steering Committee and Investigators
Sep 19, 2009·Chest·Gregory Y H LipHarry J G M Crijns
Mar 20, 2010·Chest·Ron PistersGregory Y H Lip
Oct 12, 2010·American Heart Journal·Christian T RuffEugene Braunwald
Aug 13, 2011·The New England Journal of Medicine·Manesh R PatelUNKNOWN ROCKET AF Investigators
Aug 30, 2011·The New England Journal of Medicine·Christopher B GrangerUNKNOWN ARISTOTLE Committees and Investigators
Nov 21, 2013·The New England Journal of Medicine·Robert P GiuglianoUNKNOWN ENGAGE AF-TIMI 48 Investigators
Jun 27, 2014·Circulation Journal : Official Journal of the Japanese Circulation Society·UNKNOWN JCS Joint Working Group
Jul 19, 2014·Drugs·Henri Bounameaux, A John Camm
Oct 16, 2015·Circulation Journal : Official Journal of the Japanese Circulation Society·Yuichi J ShimadaRobert P Giugliano
Apr 20, 2016·Journal of Arrhythmia·Hiroshi InoueUNKNOWN J-Dabigatran Surveillance Investigators
Dec 14, 2016·The New England Journal of Medicine·Rachel E ShermanRobert M Califf
Apr 22, 2017·Circulation Journal : Official Journal of the Japanese Circulation Society·Yugo YamashitaMasaharu Akao
Aug 3, 2017·Journal of Arrhythmia·Yasuo Okumura The Sakura Af Registry Investigators
Feb 18, 2018·Journal of the American Heart Association·Benjamin A SteinbergUNKNOWN Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF) II Investigators
Mar 22, 2018·European Heart Journal·Jan SteffelUNKNOWN ESC Scientific Document Group
Apr 17, 2018·Journal of Arrhythmia·Satoshi OgawaLyo Inuyama
Feb 7, 2019·Circulation Journal : Official Journal of the Japanese Circulation Society·Nobuhiro MurataUNKNOWN SAKURA AF Registry Investigators
Feb 10, 2019·Journal of cardiology·Hiroshi InoueUNKNOWN J-Dabigation Surveillance Investigators
Feb 13, 2019·Journal of cardiology·Takanori IkedaSatoshi Yamanaka
Feb 26, 2019·Journal of Arrhythmia·Takeshi YamashitaSeiji Kogure
Jul 12, 2019·Journal of Arrhythmia·Hiroshi InoueMasahiro Yasaka
Aug 20, 2019·Journal of cardiology·Hiroshi InoueMasahiro Yasaka
Aug 23, 2019·Journal of Thrombosis and Thrombolysis·Takanori IkedaSatoshi Yamanaka
Citations
Feb 7, 2021·Journal of Clinical Medicine·Raffaele De CaterinaPaulus Kirchhof
Jun 13, 2020·Journal of Arrhythmia·Koichi Nagashima, Yasuo Okumura
Mar 6, 2021·Journal of Arrhythmia·Tetsuji ShinoharaUNKNOWN KYU‐RABLE Investigators
Mar 6, 2021·Journal of Arrhythmia·Ryo WadaTakanori Ikeda
Apr 15, 2021·Journal of Arrhythmia·Takeshi YamashitaKazuhito Shiosakai